following an abbreviated submission:
midazolam (Epistatus®) is accepted for use within NHS Scotland.
Indication under review: treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years.
The availability of midazolam (Epistatus) provides a licensed alternative to a previously available unlicensed preparation (10mg/mL).
|Drug Name:||midazolam (Epistatus)|
|SMC Drug ID:||1279/17|
|Manufacturer:||Special Products Ltd|
|Indication:||Treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years.|
|Submission Type:||Abbreviated Submission|
|Date Advice Published:||13 November 2017|
To read more Press Release articles, click here.